8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

       Date of Report (Date of Earliest Event Reported): NOVEMBER 15, 2006


                            IRIS INTERNATIONAL, INC.
             (Exact name of registrant as specified in its charter)


         DELAWARE                        1-11181                  94-2579751
(State or other jurisdiction     (Commission File Number)     (I.R.S. Employer
   of incorporation)                                         Identification No.)

                                9172 ETON AVENUE
                              CHATSWORTH, CA 91311
                (Address of Principal Executive Offices/Zip Code)

                                 (818) 709-1244
              (Registrant's telephone number, including area code)


         Check the  appropriate  box below if the Form 8-K filing is intended to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (SEE General Instruction A.2. below):

[_]      Written  communications  pursuant to Rule 425 under the  Securities Act
         (17 CFR 230.425)

[_]      Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17
         CFR 240.14a-12)

[_]      Pre-commencement  communications  pursuant to Rule  14d-2(b)  under the
         Exchange ct (17 CFR 240.14d-2(b))

[_]      Pre-commencement  communications  pursuant to Rule 13e-4(c))  under the
         Exchange Act (17 CFR 240.13e-4c))





ITEM 5.02         DEPARTURE  OF DIRECTORS  OR  PRINCIPAL  OFFICERS;  ELECTION OF
                  DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS

                  RESIGNATION OF CURRENT  CORPORATE VICE PRESIDENT AND PRESIDENT
                  OF IRIS DIAGNOSTICS DIVISION

         Bernard M.  Alfano,  Corporate  Vice  President  and  President of IRIS
Diagnostics,  is no  longer  employed  by us.  We  consider  Mr.  Alfano to have
voluntarily resigned his employment with us effective November 15, 2006.

ITEM 9.01.        FINANCIAL STATEMENTS AND EXHIBITS

         (c)      Exhibits.

                  The following exhibits are filed herewith:

                  Exhibit
                  Number   Description
                  -------  -----------------------------------------------------
                  99.1     Press  release  issued by IRIS  International,  Inc.,
                           dated November 17, 2006.


                                       2



                                    SIGNATURE

         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  Registrant  has duly  caused  this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                          IRIS INTERNATIONAL, INC.

Date:    November 17, 2006           By:  /s/ Cesar M. Garcia
                                          --------------------------------------
                                          Cesar M. Garcia
                                          President and Chief Executive Officer


                                       3

EX-99

                                                                    EXHIBIT 99.1


IRIS REALIGNS  MANAGEMENT  FUNCTIONS AT DIAGNOSTIC  UNIT FOLLOWING  DEPARTURE OF
UNIT PRESIDENT

EXPECTS CONTINUED GROWTH IN REVENUES AND PROFITS IN 2007

CHATSWORTH,  Calif.-- IRIS  INTERNATIONAL,  INC. (NASDAQ:  IRIS) today announced
that  Dino M.  Alfano,  Corporate  Vice  President  and  President  of the  Iris
Diagnostics Business Unit, is no longer employed with the company.

"In light of Mr. Alfano's decision to leave the company, we are accelerating the
planned  realignment  of  management  functions at the Iris  Diagnostics  Unit,"
stated IRIS President and Chief Executive Officer Cesar Garcia,  who will assume
direct  responsibilities  for  the  Diagnostics  Unit  until  a  replacement  is
identified.

"The  Diagnostics  Unit is deep in seasoned  management  and has recently  added
several industry  veterans with exceptional  credentials,  each of whom is quite
experienced and successful at those activities required to accelerate an already
strong  business,"  Mr.  Garcia  said.  "We  have  recently  added a new  senior
executive to oversee the underperforming service sector and will be adding a new
head of sales to take charge of the  commercialization  of new products  planned
for 2007 and to accelerate record revenue growth."

Mr. Garcia  continued,  "We  anticipate  record  contributions  in 2007 from the
Diagnostics  Unit,  spurred  not  only  by  continuing  robust  sales,  but by a
restoration  of  higher  margins  in  the  consumables  and  service  end of the
business.  IRIS will exit 2006 with record  revenues,  a significant new product
pipeline, no debt, cash of almost $20 million and high expectations for 2007."

"The Board of Directors fully supports the initiatives taken by Mr. Garcia,  who
has  displayed  extraordinary  leadership  and resolve,"  stated Board  Chairman
Richard H.  Williams.  "We remain  confident  that,  under his  leadership,  the
management  team will deliver  results and extend our business into new areas of
diagnostics, all internally funded."

THE COMPANY

IRIS International,  Inc. (www.proiris.com),  based in Chatsworth,  Calif., is a
leader  in  automated  urinalysis  technology  with  systems  in  major  medical
institutions throughout the world. The Company's Sample Processing business unit
(formerly the StatSpin(R) subsidiary),  based in Westwood,  Mass.,  manufactures
innovative  centrifuges and blood analysis  products.  Advanced  Digital Imaging
Research,  LLC (ADIR),  based near  Houston,  Texas,  is the  Company's  imaging
research  and  development  subsidiary.  The IRIS  Molecular  Diagnostics  (IMD)
Subsidiary develops innovative ultra-sensitive diagnostics and sample processing
products with  applications in the urinalysis,  oncology and infectious  disease
markets.

SAFE HARBOR PROVISION

This news release contains forward-looking  statements made in reliance upon the
safe harbor provisions of the Private Securities  Litigation Reform Act of 1995.
Forward-looking  statements include, but are not limited to, the Company's views
on future  financial  performance,  market  growth,  capital  requirements,  new
product introductions and acquisitions,  and are generally identified by phrases
such as "thinks," "anticipates,"  "believes," "estimates," "expects," "intends,"
"plans," and similar  words.  Forward-looking  statements  are not guarantees of
future performance and are inherently subject to uncertainties and other factors
which could cause actual results to differ  materially from the  forward-looking
statement. These statements are based upon, among other things, assumptions made
by, and information currently available to, management,  including  management's
own  knowledge  and  assessment  of the  Company's  industry,  R&D  initiatives,
competition and capital requirements. Other factors and uncertainties that could
affect the Company's forward-looking statements include, among other things, the
following: identification of feasible new product initiatives, management of R&D
efforts and the  resulting  successful  development  of new products and product
platforms;  acceptance by customers of the Company's  products;  integration  of
acquired businesses;  substantial  expansion of international sales; reliance on
key suppliers;  the potential need for changes in long-term strategy in response
to future  developments;  future  advances  in  diagnostic  testing  methods and
procedures; potential





changes in government  regulations and healthcare policies,  both of which could
adversely affect the economics of the diagnostic testing procedures automated by
the Company's products;  rapid technological  change in the microelectronics and
software industries;  and competitive  factors,  including pricing pressures and
the introduction by others of new products with similar or better  functionality
than our  products.  These  and  other  risks are more  fully  described  in the
Company's  filings with the  Securities and Exchange  Commission,  including the
Company's most recently filed Annual Report on Form 10-K and Quarterly Report on
Form 10-Q, which should be read in conjunction herewith for a further discussion
of important  factors that could cause actual results to differ  materially from
those in the forward-looking statements. The Company undertakes no obligation to
publicly update or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.


CONTACT:
IRIS International, Inc.
Cesar Garcia, 818-709-1244 x 7123
Chief Executive Officer
or
The Wall Street Group, Inc.
Ron Stabiner / Paul Del Colle, 212-888-4848


                                       2